---
title: "Sentinel Surveillance Identifies Threats to SMC Effectiveness in Northern Kenya"
id: "medrxiv-2-sentinel-event-surveillance-to-identify-threats-to-smc-effectiveness"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-sentinel-event-surveillance-to-identify-threats-to-smc-effectiveness"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1"
published_at: "2026-11-12T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sentinel Surveillance Identifies Threats to SMC Effectiveness in Northern Kenya
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-sentinel-event-surveillance-to-identify-threats-to-smc-effectiveness
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1)
- **Published At:** 2026-11-12T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators implemented a sentinel-site surveillance system in northern Kenya that investigated every malaria case among **SMC**-eligible children at selected health facilities to find gaps in delivery, uptake, and effectiveness. - The study team observed that household travel was a more common reason for missing an SMC cycle than caregiver refusal, reflecting mobility and access challenges. - Data indicated that more than one-third of children presenting with malaria had missed their most recent **SMC** cycle; about 15% presented within a few days of a scheduled next cycle. - The prevalence of the SP quintuple mutant haplotype IRNI/GEAA (PfDHFR 51I, 59R, 108N; PfDHPS 437G, 540E) was 13.4% in infections sampled—markedly lower than reports from other parts of East Africa. - The allele linked to reduced susceptibility to **amodiaquine** was not detected in the sample set. - The study team reported that resistance-associated mutations were more common among children who had recently received **SPAQ**, suggesting intrahost selection after chemoprevention. - Sentinel surveillance allowed program managers to detect geographic and implementation gaps in near real time, enabling targeted SMC distribution and community sensitization activities. - Authors noted ethical approvals and that sequence data are being uploaded to NCBI SRA for public access. - The investigators concluded that continued molecular surveillance will be important as **SMC** is scaled up in mobile, remote populations, and that their approach provides a practical monitoring framework.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=UHIdiJLng4Oiz8qIwN5MTbQ6wqVDJ8DVfh7bv8hK_D0-1794514977.1778831-1.2.1.1-rzClIAHK.QhKYcKbpXavjhFCEZmcsasWziF3H6j4HFH.4waMr9qdnedp3H30JrYS) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Sentinel Event Surveillance to Identify Threats to SMC Effectiveness: Association Between Breakthrough Infections, SMC Uptake, Adherence and Parasite Drug Resistance [ View ORCID Profile](http://orcid.org/0000-0002-6938-1150)Dancan M. Wakoli, Beatrice Rotich, Edwin Mbugua, Suzanne Van Hulle, Joseph Kipkoech, [ View ORCID Profile](http://orcid.org/0000-0002-6160-839X)Lucy Abel, Thomas Katairo, Emmah Kimachas, Amy Wesolowski, Melissa Conrad, [ View ORCID Profile](http://orcid.org/0000-0003-3708-1871)Diana Menya, Wendy Prudhomme O’Meara doi: https://doi.org/10.64898/2026.11.10.26367777 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Dancan M. Wakoli 1 AMPATH Kenya; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dancan%2B%2BM.%2BWakoli%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wakoli%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADancan%2B%2BM.%2BWakoli%2B) * [ORCID record for Dancan M. Wakoli](http://orcid.org/0000-0002-6938-1150 "Open in new tab") * For correspondence: dancanwakoli@gmail.com Beatrice Rotich 1 AMPATH Kenya; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Beatrice%2BRotich%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rotich%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABeatrice%2BRotich%2B) Edwin Mbugua 2 Catholic Relief Services - USCCB; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Edwin%2BMbugua%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mbugua%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEdwin%2BMbugua%2B) Suzanne Van Hulle 3 Catholic Relief Services - United States Conference of Catholic Bishops; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Suzanne%2BVan%2BHulle%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Van%20Hulle%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASuzanne%2BVan%2BHulle%2B) Joseph Kipkoech 4 Duke Global Health Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joseph%2BKipkoech%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kipkoech%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoseph%2BKipkoech%2B) Lucy Abel 1 AMPATH Kenya; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lucy%2BAbel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Abel%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALucy%2BAbel%2B) * [ORCID record for Lucy Abel](http://orcid.org/0000-0002-6160-839X "Open in new tab") Thomas Katairo 5 Infectious Diseases Research Collaboration; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BKatairo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Katairo%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BKatairo%2B) Emmah Kimachas 1 AMPATH Kenya; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emmah%2BKimachas%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kimachas%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEmmah%2BKimachas%2B) Amy Wesolowski 6 Johns Hopkins University Bloomberg School of Public Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amy%2BWesolowski%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wesolowski%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmy%2BWesolowski%2B) Melissa Conrad 7 Johns Hopkins Bloomberg School of Public Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Melissa%2BConrad%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Conrad%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMelissa%2BConrad%2B) Diana Menya 8 Moi University College of Health Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Diana%2BMenya%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Menya%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADiana%2BMenya%2B) * [ORCID record for Diana Menya](http://orcid.org/0000-0003-3708-1871 "Open in new tab") Wendy Prudhomme O’Meara 9 Duke University School of Medicine * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wendy%2B%2BPrudhomme%2BO%E2%80%99Meara%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=O%E2%80%99Meara%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWendy%2B%2BPrudhomme%2BO%25E2%2580%2599Meara%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1343582/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1343582/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1343582/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1343582/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1343582/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Seasonal malaria chemoprevention (SMC) is an important malaria prevention strategy used widely in areas of West Africa with highly seasonal transmission. Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) to young children during the high-transmission season substantially reduces malaria morbidity and mortality. SMC has recently been introduced in northern Kenya, where pastoralist communities experience intense malaria transmission. However, implementation in this setting presents unique challenges, including population mobility, vast distances, dispersed settlements, and high levels of parasite resistance to SP in parts of the region. Effective surveillance is needed to identify gaps in SMC delivery and uptake and to monitor threats to program effectiveness. We implemented an innovative sentinel-site surveillance approach in which every malaria case among SMC-eligible children at selected health facilities was investigated to identify gaps in SMC delivery, uptake, and effectiveness. We also assessed the prevalence of parasite alleles associated with SP and AQ resistance and examined their relationship with SMC uptake. Household travel was substantially more common than caregiver refusal among reported reasons for missing an SMC cycle. More than one-third of children presenting with malaria had missed their most recent SMC cycle, while 15% were within a few days of receiving the next scheduled cycle. The prevalence of SP resistance mutations was considerably lower than reported in other parts of East Africa: only 13.4% of infections carried the quintuple mutant haplotype IRNI/GEAA (PfDHFR 51I, 59R, 108N, PfDHPS 437G, 540E) associated with high level resistance to SP. However, the prevalence of resistance-associated mutations was higher among children who had recently received SMC. The allele associated with reduced susceptibility to AQ was not detected. Sentinel surveillance identified geographic and implementation gaps in real time, allowing program managers to target SMC distribution and community sensitization. Although the prevalence of resistance-associated mutations that could threaten SPAQ effectiveness was low, evidence of intrahost selection among children who had received SMC suggests that continued molecular surveillance will be important as SMC is scaled up in northern Kenya. This sentinel surveillance approach provides a practical framework for monitoring SMC implementation in remote, highly mobile populations while simultaneously tracking emerging threats to SPAQ effectiveness. ### Competing Interest Statement The authors declare that there are no competing interests ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Moi Teaching and Referral Hospital/Moi University Institutional Scientific and Ethics Review Committee (Approval number FAN:005076). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data are being uploaded onto NCBI SRA and will be publicly available Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.10.26367774v1 "Readiness Among Female Community Health Volunteers to Deliver Community Based Tobacco Cessation Counseling in Rural Nepal: A Two-phase Mixed-methods Study")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.10.26367773v1 "Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study") Posted November 12, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/12/2026.11.10.26367777.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/12/2026.11.10.26367777.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Sentinel Event Surveillance to Identify Threats to SMC Effectiveness: Association Between Breakthrough Infections, SMC Uptake, Adherence and Parasite Drug Resistance Dancan M. Wakoli, Beatrice Rotich, Edwin Mbugua, Suzanne Van Hulle, Joseph Kipkoech, Lucy Abel, Thomas Katairo, Emmah Kimachas, Amy Wesolowski, Melissa Conrad, Diana Menya, Wendy Prudhomme O’Meara medRxiv 2026.11.10.26367777; doi: https://doi.org/10.64898/2026.11.10.26367777 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367777v1%26text%3DSentinel%2520Event%2520Surveillance%2520to%2520Identify%2520Threats%2520to%2520SMC%2520Effectiveness%253A%2520Association%2520Between%2520Breakthrough%2520Infections%252C%2520SMC%2520Uptake%252C%2520Adherence%2520and%2520Parasite%2520Drug%2520Resistance "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367777v1%26t%3DSentinel%2520Event%2520Surveillance%2520to%2520Identify%2520Threats%2520to%2520SMC%2520Effectiveness%253A%2520Association%2520Between%2520Breakthrough%2520Infections%252C%2520SMC%2520Uptake%252C%2520Adherence%2520and%2520Parasite%2520Drug%2520Resistance "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367777v1%26title%3DSentinel%2520Event%2520Surveillance%2520to%2520Identify%2520Threats%2520to%2520SMC%2520Effectiveness%253A%2520Association%2520Between%2520Breakthrough%2520Infections%252C%2520SMC%2520Uptake%252C%2520Adherence%2520and%2520Parasite%2520Drug%2520Resistance%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367777v1%26title%3DSentinel%2520Event%2520Surveillance%2520to%2520Identify%2520Threats%2520to%2520SMC%2520Effectiveness%253A%2520Association%2520Between%2520Breakthrough%2520Infections%252C%2520SMC%2520Uptake%252C%2520Adherence%2520and%2520Parasite%2520Drug%2520Resistance "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.10.26367777) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.10.26367777v1&count=horizontal&via=&text=Sentinel%20Event%20Surveillance%20to%20Identify%20Threats%20to%20SMC%20Effectiveness%3A%20Association%20Between%20Breakthrough%20Infections%2C%20SMC%20Uptake%2C%20Adherence%20and%20Parasite%20Drug%20Resistance&counturl=www.medrxiv.org/content/10.64898/2026.11.10.26367777v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (922) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (352) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5021) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (429) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (680) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1696) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16286) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://ww
## Related Clinical Research

- [Hepatitis C treatment access in Los Angeles County: barriers, facilitators, and linkage-to-cure fi](https://medichelpline.com/clinical-feed/plos-one-9-exploring-barriers-and-facilitators-to-hepatitis-c-virus-treatment-access-in.md)
- [HPV prevalence and genotype distribution in women from northern Lao PDR (2018–2019)](https://medichelpline.com/clinical-feed/plos-one-15-prevalence-and-genotype-distribution-of-human-papillomavirus-in-women-from.md)
- [NOX2 drives HBV replication via ROS-induced autophagy in cell models](https://medichelpline.com/clinical-feed/pubmed-43059380.md) (DOI: 10.3892/ijmm.2026.6054)
- [Continuous luminescence monitoring of hepatitis C virus and orthoflavivirus infections](https://medichelpline.com/clinical-feed/pubmed-42861980.md) (DOI: 10.1128/jvi.01266-26)
- [Prevalence of protective anti-HBs among women delivering at Kawempe National Referral Hospital, Ug](https://medichelpline.com/clinical-feed/medrxiv-18-prevalence-of-protective-hepatitis-b-surface-antibody-levels-and-associated.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.